Retrospective analysis found no significant difference in SSIs among antibiotic regimens for type III open fractures, suggesting piperacillin-tazobactam may reduce adverse effects.
Key Points
No significant difference in deep or superficial surgical site infections observed between antibiotic groups.
Results showed 164 patients treated with three regimens, with infection rates p = 0.41 and p = 0.52.
Single-center retrospective analysis predominantly focused on type III open fractures in trauma patients.
Findings indicate the potential equivalence of piperacillin-tazobactam to conventional regimens with possibly fewer side effects.